BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to BrainStorm Cell Therapeutics Reports Second Quarter 2016 Financial Results and Provides Corporate Update

Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 13c

August 11, 2016 8:06 AM EDT

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.05), $0.13 better than the analyst estimate of ($0.18).

Second Quarter 2016 and Recent Highlights

Announced positive topline results from U.S. Phase 2 randomized, placebo controlled study of NurOwn in patients with ALS.Study... More